AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Apr 20, 2022
31523_dirs_2022-04-20_4d465fdd-5f33-44f3-8611-c0ef2d03a4c3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-04-18
Reporting Person: Crowley John F (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-18 | Common Stock | S | 2214 | $8.0371 | Disposed | 974221 | Direct |
| 2022-04-19 | Common Stock | S | 8254 | $8.0061 | Disposed | 965967 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.15 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.00 to $8.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.